Genexo and Enzymotec to Commercialize CardiaBeat in the Polish Consumer Health Market 

11/09/07 Genexo Pharmaceuticals, a private Polish pharmaceutical company and Enzymotec, an Israeli biotechnology company, have announced on signing an agreement for launching CardiaBeat in the Polish market. The announcement follows recent launch in India by the pharmaceuticals company Elder.

Genexo is a private Polish pharmaceutical company offering innovative products for the diagnosis, treatment and prevention of metabolic diseases including diabetes, hypercholesterolemia, and obesity. The key products include Glucosense - biosensoric glucose monitoring system, Fosanic - natural treatment for the metabolic syndrome and obesity, Glipid - type 2 diabetes treatment. Well trained sales organization targets doctors and pharmacies in the territory of Poland.

CardiaBeat is an innovative proprietary ingredient which enhances the impact of plant sterols and omega-3 Fatty Acids, on cardiovascular disease (CVD) risk reduction. Earlier this year Enzymotec had announced on its European Novel Food approval as well as the publication of its clinical study outcomes at the December 2006 issue of the American Journal of Clinical Nutrition.

"I am proud that Genexo have found CardiaBeat as a complementary dietary supplement to the current drug line they have for CVD. Signing of this agreement and the recent Novel Food approval by the European heath authorities are important milestones in our sales and marketing strategy for CardiaBeat in Europe. We expect to finalize more strategic agreements before the end of this year" says Ms. Michal Haim-Bravman, Enzymotec’s marketing manager.

According to several market researches published in the last three years, the demand for dietary supplements in Poland is growing due to increasing willingness to self-medicate, the awareness for CVD and its prevention.